Abstract

The investigators hypothesize that appearance of a """"""""hyper-sensitive"""""""" ER variant might be one of the earliest genetic events in breast cancer evolution, and as such might be an early biomarker useful for the early detection and ultimate prevention of breast cancer. This hypothesis will be tested via three Specific Aims: (1) To study the function of the hyper-sensitive ER variant using estrogen-responsive mammalian expression vector systems; (2) To determine whether expression of the hyper-sensitive ER variant is associated with early breast disease and with breast cancer evolution and progression in breast specimens from several clinical studies;. (3) To determine whether the hyper-sensitive ER variant acts as a promoter or facilitator of mammary carcinogenesis in transgenic mouse models.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA072038-04
Application #
2895701
Study Section
Biochemical Endocrinology Study Section (BCE)
Program Officer
Mohla, Suresh
Project Start
1996-09-01
Project End
2001-07-31
Budget Start
1999-08-24
Budget End
2000-07-31
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Gates, Leah A; Gu, Guowei; Chen, Yue et al. (2018) Proteomic profiling identifies key coactivators utilized by mutant ER? proteins as potential new therapeutic targets. Oncogene 37:4581-4598
Carron, Emily C; Homra, Samuel; Rosenberg, Jillian et al. (2017) Macrophages promote the progression of premalignant mammary lesions to invasive cancer. Oncotarget 8:50731-50746
Gelsomino, Luca; Gu, Guowei; Rechoum, Yassine et al. (2016) ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat 157:253-265
Gu, Guowei; Fuqua, Suzanne A W (2016) ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action. Clin Cancer Res 22:1034-6
Fuqua, Suzanne A W; Rechoum, Yassine; Gu, Guowei (2016) ESR1 Mutations in Cell-Free DNA of Breast Cancer: Predictive ""Tip of the Iceberg"". JAMA Oncol 2:1315-1316
Ciupek, Andrew; Rechoum, Yassine; Gu, Guowei et al. (2015) Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ER?-positive breast cancer. Breast Cancer Res Treat 154:225-37
Gu, Guowei; Gelsomino, Luca; Covington, Kyle R et al. (2015) Targeting thyroid hormone receptor beta in triple-negative breast cancer. Breast Cancer Res Treat 150:535-45
Rechoum, Yassine; Rovito, Daniela; Iacopetta, Domenico et al. (2014) AR collaborates with ER? in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 147:473-85
Fuqua, Suzanne A W; Gu, Guowei; Rechoum, Yassine (2014) Estrogen receptor (ER) ? mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat 144:11-9

Showing the most recent 10 out of 51 publications